A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Gemcitabine (Primary) ; Okaymipasetamab uzoptirine (Primary)
- Indications Adenocarcinoma; Bladder cancer; Cervical cancer; Chondrosarcoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Soft tissue sarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions
- Sponsors ADC Therapeutics
- 06 May 2024 According to an ADC Therapeutics media release, additional data updates from the Phase 1 study in patients with sarcoma, pancreatic cancer and NSCLC expected in 2H 2024
- 17 Apr 2024 Planned number of patients changed from 196 to 260.
- 13 Mar 2024 According to an ADC Therapeutics media release, additional data updates from the Phase 1 study in patients with sarcoma, pancreatic cancer and NSCLC in 2024